ライフサイエンスコーパス: dronedarone

1 conazole, voriconazole, or posaconazole; and dronedarone.

2 e among patients who received treatment with dronedarone.

3 and liver disease among patients exposed to dronedarone.

4 to investigate the inactivation of CYP450 by dronedarone.

5 regarding clinical efficacy of azimilide and dronedarone.

6 goxin, there were 6 cardiovascular deaths on dronedarone (1.7%/year) and 8 on placebo (2.2%/year; adj

7 The electrophysiological effects of dronedarone (10 mumol/l) and a relatively low concentrat

8 ebo (P=0.008), whereas ranolazine 750 mg BID/dronedarone 150 mg BID reduced AFB by 43% (P=0.072).

9 Conversely, ranolazine 750 mg BID/dronedarone 225 mg BID reduced AFB by 59% versus placebo

10 We identified 4 placebo-controlled trials of dronedarone, 4 placebo-controlled trials of amiodarone,

11 Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascu

12 Of these, 4,856 patients had received dronedarone according to the Swedish Drug Register, and

13 d to placebo, ranolazine alone (750 mg BID), dronedarone alone (225 mg BID), or one of the combinatio

14 ntration on day 7 was 1.1 (0.7,1.5) ng/mL on dronedarone and 0.7 (0.5,1.1) ng/mL on placebo (P<0.001)

15 In PALLAS, 1619 patients were randomized to dronedarone and 1617 to placebo, of whom 544 (33.6%) and

16 were 15 (8.6%/year) cardiovascular deaths on dronedarone and 2 (1.2%/year) on placebo (adjusted hazar

17 n digoxin, there were 2 arrhythmic deaths on dronedarone and 4 on placebo (P value for interaction 0.

18 on are 2.19 microM and 0.0056 minute(-1) for dronedarone and 5.45 microM and 0.056 minute(-1) for NDB

19 We demonstrated for the first time that both dronedarone and its main metabolite N-desbutyl dronedaro

20 In conclusion, dronedarone and NDBD inactivate CYP3A4 and CYP3A5 via un

21 both CYP3A4 and CYP3A5 from inactivation by dronedarone and NDBD.

22 ived from the quinone oxime intermediates of dronedarone and NDBD.

23 digoxin, there were 11 arrhythmic deaths on dronedarone and none on placebo; and in patients not on

24 The combination of dronedarone and ranolazine caused little change in actio

25 aluate the effectiveness of a combination of dronedarone and ranolazine in suppression of atrial fibr

26 that raise questions regarding the safety of dronedarone and several new promising techniques in AF a

27 New antiarrhythmic drugs, such as dronedarone and vernakalant, have provided some addition

28 croM and 0.039 minute(-1), respectively, for dronedarone, and 6.24 microM and 0.099 minute(-1), respe

29 summarize the available evidence concerning dronedarone, and offer practical recommendations to heal

30 for the inactivation of CYP3A4 and CYP3A5 by dronedarone are 51.1 and 32.2, and the partition ratios

31 The electrophysiological effects of dronedarone are similar to those of AM but more potent,

32 ctive investigation, including azimilide and dronedarone, are compounds with multiple electrophysiolo

33 Dronedarone, as prescribed to AF patients in Sweden, has

34 Dronedarone caused little or no change in electrophysiol

35 The present analysis examines whether the dronedarone-digoxin interaction might explain these adve

36 olazine (750 mg BID) combined with 2 reduced dronedarone doses (150 mg BID and 225 mg BID; chosen to

37 There has been concern about the safety of dronedarone, especially for patients with heart failure

38 oup and 102.3+/-24.7 beats per minute in the dronedarone group (P<0.001); the corresponding rates in

39 days in the placebo group and 96 days in the dronedarone group (P=0.01).

40 tion were not significantly increased in the dronedarone group.

41 ustment for cofactors, patients who received dronedarone had lower mortality than other AF patients (

42 ad the lowest risk of AF hospitalization and dronedarone had the greatest risk.

43 view evidence of safety and effectiveness of dronedarone in patients with atrial fibrillation.

44 e that the available data support the use of dronedarone in select patient populations as a second- o

45 Dronedarone increases digoxin concentration by P-glycopr

46 of the underlying mechanisms associated with dronedarone-induced hepatotoxicity and clinical drug-dru

47 in-house preliminary study demonstrated that dronedarone inhibits cytochrome P450 (CYP) 3A4 and 3A5 i

48 For every 1,000 patients treated with dronedarone instead of amiodarone, we estimate approxima

49 Dronedarone is a new antiarrhythmic agent pharmacologica

50 Dronedarone is a new antiarrhythmic agent that was recen

51 Dronedarone is a noniodinated amiodarone congener develo

52 Dronedarone is a noniodinated benzofuran derivative of a

53 Similar to amiodarone, dronedarone is a potent blocker of multiple ion currents

54 Dronedarone is an antiarrhythmic agent approved in 2009

55 Dronedarone is less effective than amiodarone for the ma

56 onedarone and its main metabolite N-desbutyl dronedarone (NDBD) inactivate CYP3A4 and CYP3A5 in a tim

57 ible metabolite-intermediate complex between dronedarone/NDBD and CYP3A4/CYP3A5, partial recovery of

58 current digoxin use on the adverse effect of dronedarone on cardiovascular death, but not on occurren

59 seline digoxin use and the adverse effect of dronedarone on heart failure events.

60 nent Atrial Fibrillation Outcome Study Using Dronedarone On Top Of Standard Therapy Trial (PALLAS), d

61 clinical trials have evaluated the impact of dronedarone on various cardiovascular end points and yie

62 Separately, dronedarone or a low concentration of ranolazine prevent

63 rolled trials in which the authors evaluated dronedarone or amiodarone for the prevention of AF.

64 trial evidence found amiodarone superior to dronedarone (OR: 0.49; 95% CI: 0.37 to 0.63; p < 0.001)

65 drug discontinuation with amiodarone versus dronedarone (OR: 1.81; 95% CI: 1.33 to 2.46; p < 0.001).

66 first AAD prescription (amiodarone, sotalol, dronedarone, or Class Ic) within 14 days post-first AF e

67 Dronedarone patients with heart failure had lower mortal

68 Low concentrations of ranolazine and dronedarone produce relatively weak electrophysiological

69 Dronedarone reduces mortality and morbidity in patients

70 yclosporine; erythromycin or clarithromycin; dronedarone; rifampin; or phenytoin.

71 (150 mg BID and 225 mg BID; chosen to reduce dronedarone's negative inotropic effect-see text below)

72 amiodarone (AM), its noniodinated analogue, dronedarone (SR), was synthesized.

73 Dronedarone, tedisamal, and trecetilide are now under ac

74 risk of AF hospitalization was greater with dronedarone than Class Ic (hazard ratio [HR] 1.59; 95% c

75 sought to compare the efficacy and safety of dronedarone versus amiodarone for the prevention of recu

76 directly compare the efficacy and safety of dronedarone versus amiodarone.

77 trolled trials of amiodarone, and 1 trial of dronedarone versus amiodarone.

78 fidence interval [CI]: 0.08 to 0.19) but not dronedarone versus placebo (OR: 0.79; 95% CI: 0.33 to 1.

79 l mortality rate among patients who received dronedarone was 1.3% compared with 14.0% in the control

80 e On Top Of Standard Therapy Trial (PALLAS), dronedarone was associated with both increased cardiovas

81 Dronedarone was significantly more effective than placeb

82 The effect of amiodarone versus dronedarone was summarized by the use of indirect compar

83 Patients prescribed dronedarone were younger (age 65.5 years vs. 75.7 years,

84 y moderate dose ranolazine plus reduced dose dronedarone, with good tolerance/safety, in the populati